Ignite Creation Date:
2024-05-05 @ 11:43 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00117273
Status:
COMPLETED
Last Update Posted:
2014-05-09
First Post:
2005-06-30
Brief Title:
A Study to Evaluate Suppression of the Pituitary-Ovarian Axis With Three Different Oral Contraceptive Regimens
Sponsor:
Duramed Research
Organization:
Teva Branded Pharmaceutical Products RD Inc
Study Overview
Official Title:
A Prospective Single-Center Open-Label Randomized Study to Evaluate Suppression of the Pituitary-Ovarian Axis With Three Different Regimens of Oral Contraceptive Pills
Status:
COMPLETED
Status Verified Date:
2014-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a randomized open-label study to evaluate pituitary ovarian suppression in healthy reproductive-aged women using three different regimens of oral contraceptives OCs Two extended regimen OCs Seasonale levonorgestrelethinyl estradiol 015003 mg for 84 days followed by 7 days of placebo and Seasonique levonorgestrelethinyl estradiol 015003 mg for 84 days followed by 7 days of ethinyl estradiol 001 mg and a 28-day regimen OC Portia levonorgestrelethinyl estradiol 015003 mg for 21 days followed by 7 days of placebo
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None